There have been promising results in phase I studies using anti-PD-1 medications like nivolumab and pembrolizumab in patients with NSCLC, metastatic melanoma, or renal-cell carcinoma, as well as other solid tumors. This evidence concerns the gene PDCD1 and hereditary clear cell renal cell carcinoma.